In conclusion, should the anti-inflammatory drug tocilizumab prove effective in lowering proBNP levels and improving myocardial salvage, it would support the hypothesis that early immunomodulatory intervention can benefit AMI patients at risk of developing CS. This evidence concerns the gene NPPB and Cowden syndrome 1.